Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics

Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe

This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway

GSK secures European nod for easier-to-use Shingrix prefilled syringe

The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration

World First: Heart bypass without opening the chest achieved by NIH and Emory Team

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Acesion Pharma launches Phase 2 trial for groundbreaking atrial fibrillation therapy

The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint

Medera doses final patient in high-dose HFpEF gene therapy trial

Heart failure affects an estimated 64.3 million people worldwide

Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM

Bayer wins Japan nod for finerenone in broad heart failure population

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients

Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management

Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial